Related Articles
The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials
Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma
Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer
Prognostic value of programmed cell death ligand‑1 expression in the tumor‑infiltrating immune cells of patients with lung cancer: A meta‑analysis